Literature DB >> 15585893

T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

Markus Chmielewski1, Andreas Hombach, Claudia Heuser, Gregory P Adams, Hinrich Abken.   

Abstract

Chimeric TCRs with an Ab-derived binding domain confer predefined specificity and MHC-independent target binding to T cells for use in adoptive immunotherapy. We investigated the impact of receptor binding affinity on the activation of grafted T cells. A series of anti-ErbB2 single-chain fragment binding domains with a K(d) ranging from 3.2 x 10(-7) to 1.5 x 10(-11) M was linked to CD3zeta-derived immunoreceptors and expressed in human PBL. Solid phase bound ErbB2 protein triggered activation of receptor-grafted T cells in a dose-dependent manner. The activation threshold inversely correlated with the affinity of the receptor binding domain. The maximum level of cellular activation, however, was the same and independent of the binding affinity. Upon binding to ErbB2(+) cells, T cells grafted with immunoreceptors carrying a single-chain fragment of K(d) < 10(-8) M were activated in a similar fashion against cells with different amounts of ErbB2 on the surface. T cells with a low affinity receptor (K(d) > 10(-8) M), however, were activated exclusively by cells with high amounts of ErbB2. In conclusion, recombinant immunoreceptors of higher affinity do not necessarily induce a more potent activation of T cells than low affinity immunoreceptors, but the higher affinity immunoreceptors exhibit less discrimination between target cells with high or low Ag expression levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585893     DOI: 10.4049/jimmunol.173.12.7647

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  104 in total

Review 1.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

2.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

Review 3.  Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.

Authors:  Maya Suzuki; Kevin J Curran; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2015-04-01       Impact factor: 3.167

4.  A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

Authors:  Esther Drent; Maria Themeli; Renée Poels; Regina de Jong-Korlaar; Huipin Yuan; Joost de Bruijn; Anton C M Martens; Sonja Zweegman; Niels W C J van de Donk; Richard W J Groen; Henk M Lokhorst; Tuna Mutis
Journal:  Mol Ther       Date:  2017-05-13       Impact factor: 11.454

5.  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.

Authors:  Waleed Haso; Daniel W Lee; Nirali N Shah; Maryalice Stetler-Stevenson; Constance M Yuan; Ira H Pastan; Dimiter S Dimitrov; Richard A Morgan; David J FitzGerald; David M Barrett; Alan S Wayne; Crystal L Mackall; Rimas J Orentas
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

Review 6.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines.

Authors:  Sunil S Raikar; Lauren C Fleischer; Robert Moot; Andrew Fedanov; Na Yoon Paik; Kristopher A Knight; Christopher B Doering; H Trent Spencer
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

8.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Authors:  Anna Kruschinski; Andreas Moosmann; Isabel Poschke; Håkan Norell; Markus Chmielewski; Barbara Seliger; Rolf Kiessling; Thomas Blankenstein; Hinrich Abken; Jehad Charo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

Review 9.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

10.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Authors:  Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.